Levosimendan Kalceks

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer presented as an intravenous solution for IV use. It enhances cardiac contractility and promotes vasodilation, and is employed in the management of acute decompensated heart failure in adult patients.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product for global distribution, offering reliable logistics and comprehensive technical support.

Levosimendan is indicated for conditions involving severe cardiac dysfunction where rapid hemodynamic improvement is required.

- Acute decompensated heart failure: improves cardiac output and relieves symptoms of low perfusion. - Cardiogenic shock: provides inotropic support to stabilize blood pressure and organ perfusion. - Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility to facilitate weaning from mechanical support.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: transient drop in blood pressure after infusion. - Headache: mild to moderate intensity during treatment. - Nausea: occasional gastrointestinal discomfort. - Tachycardia: increased heart rate observed in some patients.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Severe hypotension: profound blood pressure fall requiring intervention.

Levosimendan requires careful monitoring and specific precautions before and during therapy.

- Renal impairment: monitor renal function and adjust supportive measures. - Hepatic impairment: use with caution and observe liver enzymes. - Hypotension: continuous blood pressure monitoring is essential. - Concomitant vasodilators: increased risk of additive blood pressure reduction. - Arrhythmias: ECG surveillance recommended during infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Phosphodiesterase inhibitors: heightened risk of severe hypotension. - Other inotropes: may cause excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor blood pressure for additive lowering. - Diuretics: watch for electrolyte imbalances. - Anticoagulants: observe for increased bleeding tendency.